Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy and to explore a more effective treatment strategy for this patient population.

Trial Details

NCT ID
NCT07255963
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Pirtobrutinib
  • Lisaftoclax
  • Rituximab
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • ≥18 years old.
  • Capable of understanding and voluntarily signing written informed consent.
  • ECOG performance 0 \~ 3.
  • Anticipated survival ≥3 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →